title: Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
abstract: BACKGROUND
  Bladder cancer is a frequently occurring tumour in Spain and usually affects elderly patients with renal impairment. The development of new combination therapies for such patients is thus of vital importance.
  
  
  METHODS
  Between 1997 and 1998, 17 patients with locally advanced non-surgical or metastatic bladder tumours were treated at our centres. Treatment consisted of 1,000 mg/m(2) of gemcitabine administered on days 1 and 8, and carboplatin (area under the concentration curve = 5) on day 1, every 21 days.
  
  
  RESULTS
  The mean age of the patients [4 females (26%) and 13 males] was 69 years (range: 54-78 years). The average Karnofsky performance status was 80% (range: 50-100%). Mean creatinine clearance was 45.4 ml/min (range: 21-55 ml/min). There were 2 complete responses, 7 partial responses (RO: 56%; range 31-81%), 6 patients had stable disease and 1 disease progression. Haematological toxicities were as follows: grade I anaemia in 2 patients, grade III in 3; grade I granulocytopenia in 2 patients, grade III-IV in 4 patients; grade III thrombocytopenia in 3 patients. Toxic death occurred in the course of one grade IV neutropenic event. Non-haematological toxicities were as follows: grade I-II vomiting in 3 patients and grade III in 1. One patient had grade III hepatic toxicity. One patient had grade III renal toxicity, and 3 patients grade II alopecia.
  
  
  CONCLUSIONS
  The above-mentioned treatment has low toxicity, is easy to administer and offers promising results in this group of patients.
authors.affiliation: Oncology Unit, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Spain. 90604@imas.imim.es
authors.forename: J
authors.initials: J
authors.lastname: Carles
authors.forename: M
authors.initials: M
authors.lastname: Nogué
authors.forename: M
authors.initials: M
authors.lastname: Domènech
authors.forename: C
authors.initials: C
authors.lastname: Pérez
authors.forename: E
authors.initials: E
authors.lastname: Saigí
authors.forename: K
authors.initials: K
authors.lastname: Villadiego
authors.forename: I
authors.initials: I
authors.lastname: Guasch
authors.forename: R
authors.initials: R
authors.lastname: Ibeas
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001773:Blood Cells / Q000187:drug effects; D016190:Carboplatin / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000150:complications / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine